Novo Nordisk signs licensing deal with Chinese pharma firm for weight loss pill
Novo Nordisk has partnered with China's Hengrui Pharma to develop a weekly weight loss pill in a deal worth up to 17.1 billion DKK.
2026年9月29日
/ DANGDI / DANGDI / DANGDI /Danish drug giant Novo Nordisk signed a license deal with China's Hengrui Pharma.
The agreement expands Novo's pipeline through Chinese pharma collaboration.
Novo gets exclusive global rights to develop and sell a new weight loss pill.
These rights exclude mainland China, Hong Kong, and Taiwan.
Hengrui Pharma is one of China's largest drug companies.
The candidate drug is named HRS-1596.
It is currently in phase 1 clinical trials.
The drug is designed for obesity treatment.
Patients might take it once a week in pill form.
The deal could be worth up to 2.6 billion dollars.
That sum equals about 17.1 billion Danish kroner.
The final payout depends on clinical trials and market launch.
The story was reported by Danish broadcaster DR.
Source: DR Nyheder
